How do you know an imaging outcome measure works the way it's supposed to? 𝐘𝐨𝐮 𝐝𝐞𝐯𝐞𝐥𝐨𝐩 𝐚𝐧𝐝 𝐯𝐚𝐥𝐢𝐝𝐚𝐭𝐞 𝐢𝐭 𝐫𝐢𝐠𝐨𝐫𝐨𝐮𝐬𝐥𝐲. For a decade, our medical research and development team, in collaboration with many other researchers around the globe, has helped shape the field by developing and validating MR-based outcome measures for Crohn's disease, spanning luminal, perianal, and fibrostenosing phenotypes. We know that rigorously developed outcome measures lead to more efficient clinical trials and better quality data. That is why are investing in Medical R&D to improve the assessment and scoring of disease activity in Crohn’s disease types and complications. This is what 𝐆𝐈 𝐈𝐬 𝐎𝐮𝐫 𝐖𝐡𝐲 looks like in practice. 📌 Read the publications: 𝘙𝘦𝘭𝘪𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘰𝘧 𝘮𝘦𝘢𝘴𝘶𝘳𝘪𝘯𝘨 𝘪𝘭𝘦𝘰-𝘤𝘰𝘭𝘰𝘯𝘪𝘤 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺 𝘣𝘺 𝘔𝘙𝘌 Jairath, 2018, Inflamm Bowel Dis. 👉 loom.ly/pI6jF5I 𝘙𝘦𝘴𝘱𝘰𝘯𝘴𝘪𝘷𝘦𝘯𝘦𝘴𝘴 𝘰𝘧 𝘔𝘙𝘌 𝘪𝘯𝘥𝘪𝘤𝘦𝘴 𝘧𝘰𝘳 𝘦𝘷𝘢𝘭𝘶𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘭𝘶𝘮𝘪𝘯𝘢𝘭 𝘥𝘪𝘴𝘦𝘢𝘴𝘦 𝘢𝘤𝘵𝘪𝘷𝘪𝘵𝘺 𝘪𝘯 𝘊𝘋 Hanžel, 2022, Clin Gastroenterol Hepatol. 👉 loom.ly/HAVRy2E 𝘋𝘦𝘷𝘦𝘭𝘰𝘱𝘮𝘦𝘯𝘵 𝘢𝘯𝘥 𝘷𝘢𝘭𝘪𝘥𝘢𝘵𝘪𝘰𝘯 𝘰𝘧 𝘢𝘯 𝘔𝘙𝘐 𝘪𝘯𝘥𝘦𝘹 𝘵𝘰 𝘢𝘴𝘴𝘦𝘴𝘴 𝘧𝘪𝘴𝘵𝘶𝘭𝘢𝘴 𝘪𝘯 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘪𝘵𝘩 𝘊𝘋 Hindryckx, 2019, Gastroenterology 👉 loom.ly/ApjYVgA 𝘙𝘦𝘭𝘪𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘰𝘧 𝘔𝘙𝘌 𝘧𝘦𝘢𝘵𝘶𝘳𝘦𝘴 𝘧𝘰𝘳 𝘥𝘦𝘴𝘤𝘳𝘪𝘣𝘪𝘯𝘨 𝘧𝘪𝘣𝘳𝘰𝘴𝘵𝘦𝘯𝘰𝘴𝘪𝘯𝘨 𝘊𝘋 Rieder, 2024, Radiology 👉 loom.ly/RV6Tz1s 𝘙𝘦𝘭𝘪𝘢𝘣𝘪𝘭𝘪𝘵𝘺 𝘰𝘧 𝘊𝘛 𝘦𝘯𝘵𝘦𝘳𝘰𝘨𝘳𝘢𝘱𝘩𝘺 𝘧𝘰𝘳 𝘥𝘦𝘴𝘤𝘳𝘪𝘣𝘪𝘯𝘨 𝘧𝘪𝘣𝘳𝘰𝘴𝘵𝘦𝘯𝘰𝘴𝘪𝘯𝘨 𝘊𝘋 Rieder, 2024, Radiology 👉 loom.ly/LmgBbTY We are grateful to all of our academic partners over the last decade who have helped shape these studies. #MagneticResonance #CrohnsDisease #GIIsOurWhy

In our 𝗚𝗜 𝗜𝘀 𝗠𝘆 𝗪𝗵𝘆 series, we’re focusing on the compassion behind the mission: standing with patients whose challenges often go unnoticed and advancing research that truly makes a difference. “𝘐 𝘤𝘩𝘰𝘰𝘴𝘦 𝘵𝘰 𝘸𝘰𝘳𝘬 𝘪𝘯 𝘎𝘐 𝘵𝘰 𝘴𝘶𝘱𝘱𝘰𝘳𝘵 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘸𝘩𝘰 𝘰𝘧𝘵𝘦𝘯 𝘴𝘵𝘳𝘶𝘨𝘨𝘭𝘦 𝘪𝘯 𝘴𝘪𝘭𝘦𝘯𝘤𝘦. 𝘐’𝘮 𝘮𝘰𝘵𝘪𝘷𝘢𝘵𝘦𝘥 𝘣𝘺 𝘵𝘩𝘦 𝘪𝘮𝘱𝘢𝘤𝘵 𝘰𝘶𝘳 𝘳𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘤𝘢𝘯 𝘩𝘢𝘷𝘦, 𝘢𝘯𝘥 𝘐 𝘳𝘦𝘮𝘢𝘪𝘯 𝘤𝘰𝘮𝘮𝘪𝘵𝘵𝘦𝘥 𝘣𝘦𝘤𝘢𝘶𝘴𝘦 𝘦𝘷𝘦𝘳𝘺 𝘴𝘵𝘦𝘱 𝘧𝘰𝘳𝘸𝘢𝘳𝘥 𝘪𝘯 𝘢 𝘵𝘳𝘪𝘢𝘭 𝘣𝘳𝘪𝘯𝘨𝘴 𝘶𝘴 𝘤𝘭𝘰𝘴𝘦𝘳 𝘵𝘰 𝘪𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘴𝘰𝘮𝘦𝘰𝘯𝘦’𝘴 𝘭𝘪𝘧𝘦.” — Nitu Agarwal, Sr. Proposal Specialist

💚 August is #GastroparesisAwarenessMonth. This month, we recognize the millions of people around the world living with #gastroparesis, a chronic condition with debilitating symptoms and complications. Despite its significant burden, treatment options are limited. As a CRO focused exclusively on GI diseases, we're committed to advancing research to address this unmet need. By partnering with sponsors to accelerate clinical trials, we're working together toward better outcomes for patients. Because #GIIsOurWhy. #GPImpact #Gastroenterology

𝗪𝗵𝘆 𝗦𝗶𝘁𝗲𝘀 𝗖𝗵𝗼𝗼𝘀𝗲 𝗔𝗹𝗶𝗺𝗲𝗻𝘁𝗶𝘃 We provide sites with clarity and resources to run smoother studies, while protecting patient safety and data integrity. • 𝗗𝗲𝗱𝗶𝗰𝗮𝘁𝗲𝗱 𝗼𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝘁𝗲𝗮𝗺𝘀—so you can focus on patient care, not admin • 𝗧𝗿𝗮𝗶𝗻𝗶𝗻𝗴 𝗮𝗻𝗱 𝗿𝗲𝘀𝗼𝘂𝗿𝗰𝗲𝘀—GI-focused and -trained CRAs who understand protocol nuances • 𝗖𝗼𝗻𝘀𝗶𝘀𝘁𝗲𝗻𝘁 𝗼𝘃𝗲𝗿𝘀𝗶𝗴𝗵𝘁—clear communication and ongoing support throughout the study Build a better trial: loom.ly/wImA94A #CRO #GIResearch #GIIsOurWhy

As part of our 𝗚𝗜 𝗜𝘀 𝗠𝘆 𝗪𝗵𝘆 series, we’re amplifying the voices of colleagues whose personal journeys fuel a deep sense of purpose — a commitment to work that brings hope and advances understanding for families like their own. “𝘞𝘩𝘦𝘯 𝘐 𝘳𝘦𝘧𝘭𝘦𝘤𝘵 𝘰𝘯 𝘸𝘩𝘺 𝘐 𝘢𝘮 𝘩𝘦𝘳𝘦 𝘵𝘰𝘥𝘢𝘺, 𝘵𝘩𝘦 𝘢𝘯𝘴𝘸𝘦𝘳 𝘪𝘴 𝘴𝘪𝘮𝘱𝘭𝘦: 𝘱𝘶𝘳𝘱𝘰𝘴𝘦. 𝘈 𝘥𝘦𝘦𝘱𝘭𝘺 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭, 𝘢𝘭𝘮𝘰𝘴𝘵 𝘪𝘯𝘴𝘵𝘪𝘯𝘤𝘵𝘪𝘷𝘦 𝘴𝘦𝘯𝘴𝘦 𝘰𝘧 𝘮𝘪𝘴𝘴𝘪𝘰𝘯. 𝘐 𝘸𝘢𝘯𝘵 𝘵𝘰 𝘣𝘦 𝘱𝘢𝘳𝘵 𝘰𝘧 𝘸𝘰𝘳𝘬 𝘵𝘩𝘢𝘵 𝘮𝘢𝘵𝘵𝘦𝘳𝘴—𝘸𝘰𝘳𝘬 𝘵𝘩𝘢𝘵 𝘰𝘧𝘧𝘦𝘳𝘴 𝘩𝘰𝘱𝘦, 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘴 𝘶𝘯𝘥𝘦𝘳𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨, 𝘢𝘯𝘥 𝘮𝘢𝘬𝘦𝘴 𝘭𝘪𝘧𝘦 𝘣𝘦𝘵𝘵𝘦𝘳 𝘧𝘰𝘳 𝘱𝘦𝘰𝘱𝘭𝘦 𝘭𝘪𝘬𝘦 𝘮𝘺 𝘥𝘢𝘶𝘨𝘩𝘵𝘦𝘳, 𝘭𝘪𝘬𝘦 𝘮𝘺𝘴𝘦𝘭𝘧, 𝘢𝘯𝘥 𝘭𝘪𝘬𝘦 𝘴𝘰 𝘮𝘢𝘯𝘺 𝘧𝘢𝘮𝘪𝘭𝘪𝘦𝘴 𝘸𝘢𝘭𝘬𝘪𝘯𝘨 𝘢 𝘴𝘪𝘮𝘪𝘭𝘢𝘳 𝘱𝘢𝘵𝘩. 𝘈𝘭𝘪𝘮𝘦𝘯𝘵𝘪𝘷’𝘴 𝘮𝘪𝘴𝘴𝘪𝘰𝘯 𝘢𝘭𝘪𝘨𝘯𝘴 𝘸𝘪𝘵𝘩 𝘮𝘺 𝘩𝘦𝘢𝘳𝘵, 𝘮𝘺 𝘩𝘪𝘴𝘵𝘰𝘳𝘺, 𝘢𝘯𝘥 𝘵𝘩𝘦 𝘫𝘰𝘶𝘳𝘯𝘦𝘺 𝘐’𝘷𝘦 𝘭𝘪𝘷𝘦𝘥.” — Monika Senk, Sr. Manager, Clinical Vendor Management

𝗦𝗰𝗮𝗹𝗲 𝗦𝗺𝗮𝗿𝘁𝗲𝗿 Take the leap from pre-clinical to clinical with GI specialists and regulatory experts on your team. Alimentiv provides senior medical and operational oversight to help #biotech companies design, plan, and execute GI clinical trials with confidence. Start your trial off strong: loom.ly/wImA94A #GIIsOurWhy #Biotech #ClinicalTrials

As part of our 𝗚𝗜 𝗜𝘀 𝗠𝘆 𝗪𝗵𝘆 series, we’re sharing the personal motivations that drive our colleagues to advance GI science — in their own voices. “𝘛𝘩𝘦 𝘸𝘰𝘳𝘬 𝘸𝘦 𝘥𝘰 𝘪𝘴 𝘯𝘰𝘵 𝘢𝘣𝘴𝘵𝘳𝘢𝘤𝘵 - 𝘪𝘵 𝘳𝘦𝘱𝘳𝘦𝘴𝘦𝘯𝘵𝘴 𝘩𝘰𝘱𝘦 𝘧𝘰𝘳 𝘱𝘢𝘵𝘪𝘦𝘯𝘵𝘴 𝘢𝘯𝘥 𝘧𝘢𝘮𝘪𝘭𝘪𝘦𝘴 𝘭𝘪𝘬𝘦 𝘮𝘪𝘯𝘦. 𝘌𝘷𝘦𝘳𝘺 𝘴𝘵𝘶𝘥𝘺, 𝘦𝘷𝘦𝘳𝘺 𝘮𝘪𝘭𝘦𝘴𝘵𝘰𝘯𝘦, 𝘢𝘯𝘥 𝘦𝘷𝘦𝘳𝘺 𝘢𝘥𝘷𝘢𝘯𝘤𝘦𝘮𝘦𝘯𝘵 𝘣𝘳𝘪𝘯𝘨𝘴 𝘶𝘴 𝘤𝘭𝘰𝘴𝘦𝘳 𝘵𝘰 𝘪𝘮𝘱𝘳𝘰𝘷𝘪𝘯𝘨 𝘤𝘢𝘳𝘦 𝘢𝘯𝘥 𝘰𝘶𝘵𝘤𝘰𝘮𝘦𝘴 𝘧𝘰𝘳 𝘵𝘩𝘰𝘴𝘦 𝘭𝘪𝘷𝘪𝘯𝘨 𝘸𝘪𝘵𝘩 𝘎𝘐 𝘥𝘪𝘴𝘦𝘢𝘴𝘦. 𝘎𝘐 𝘪𝘴 𝘮𝘰𝘳𝘦 𝘵𝘩𝘢𝘯 𝘢 𝘵𝘩𝘦𝘳𝘢𝘱𝘦𝘶𝘵𝘪𝘤 𝘢𝘳𝘦𝘢 𝘵𝘰 𝘮𝘦 - 𝘪𝘵 𝘪𝘴 𝘱𝘦𝘳𝘴𝘰𝘯𝘢𝘭, 𝘱𝘶𝘳𝘱𝘰𝘴𝘦𝘧𝘶𝘭, 𝘢𝘯𝘥 𝘱𝘳𝘰𝘧𝘰𝘶𝘯𝘥𝘭𝘺 𝘮𝘦𝘢𝘯𝘪𝘯𝘨𝘧𝘶𝘭.” — Karima Noordin, Sr Clinical Project Manager

𝗜𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗶𝗻𝗴: 𝙂𝙄 𝙄𝙨 𝙈𝙮 𝙒𝙝𝙮 At Alimentiv, GI isn’t just the focus of our work — it’s the purpose that connects us. 💜 We’re proud to launch 𝗚𝗜 𝗜𝘀 𝗠𝘆 𝗪𝗵𝘆, a new series sharing the personal motivations that drive our colleagues to advance GI science. Alimentarians bring passion, curiosity, and a deep commitment to improving outcomes for patients living with GI disease. Each story reflects who we are as one Alimentiv: a community united by purpose, inspired by impact, and driven to push GI research forward. 𝗚𝗜 𝗜𝘀 𝗢𝘂𝗿 𝗪𝗵𝘆 — 𝗮𝗻𝗱 𝘁𝗵𝗲𝘀𝗲 𝗮𝗿𝗲 𝘁𝗵𝗲 𝘃𝗼𝗶𝗰𝗲𝘀 𝘁𝗵𝗮𝘁 𝗯𝗿𝗶𝗻𝗴 𝗶𝘁 𝘁𝗼 𝗹𝗶𝗳𝗲.

It’s almost time for the Brazilian Week of Inflammatory Bowel Diseases (#SEBRADII)! Meet with Anderson Porto, Director, Regional Clinical Operations to discuss how our #GI-specialized team can support your next trial. Schedule a meeting: loom.ly/dWZKyFg GEDIIB - Organização Brasileira de Doença de Crohn e Colite #SEBRADII2026 #GIIsOurWhy

𝗪𝗵𝘆 𝗗𝗼 𝗢𝘂𝗿 #𝗣𝗵𝗮𝗿𝗺𝗮 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀 𝗖𝗵𝗼𝗼𝘀𝗲 𝗔𝗹𝗶𝗺𝗲𝗻𝘁𝗶𝘃? We provide the scale, precision, and GI experience to meet your needs—whether that’s collaborating with internal expertise or leading the program from end to end. 🌏 𝗚𝗹𝗼𝗯𝗮𝗹 𝗶𝗻𝗳𝗿𝗮𝘀𝘁𝗿𝘂𝗰𝘁𝘂𝗿𝗲: A network of 5000+ sites in 60+ countries 🩺 𝗣𝗿𝗼𝘃𝗲𝗻 𝗲𝘅𝗽𝗲𝗿𝘁𝗶𝘀𝗲: Experience in protocol design, regulatory strategy, and operational excellence 🌱 𝗦𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗶𝗹𝗶𝘁𝘆: Commitment to sustainability recognized by EcoVadis Partner with a team built for GI research: loom.ly/xyE2kRE #ClinicalTrials #GI #ESG #GIIsOurWhy

The burden of digestive disease goes beyond symptoms. From long waits for answers to limited treatment options, these diseases can severely impact quality of life. Chloe Knispel, Database Programmer at Alimentiv, has experienced this firsthand—and finds meaning in our purpose to advance effective treatments for GI diseases. We’re sharing perspectives from the people behind our work through our 𝗢𝗻𝗲 𝗣𝘂𝗿𝗽𝗼𝘀𝗲, 𝗠𝗮𝗻𝘆 𝗦𝘁𝗼𝗿𝗶𝗲𝘀 series. This purpose unites us—to build better trials alongside our sponsors, bringing better treatments to patients. Because 𝗚𝗜 𝗜𝘀 𝗢𝘂𝗿 𝗪𝗵𝘆. #DigestiveDisease #GIIsOurWhy #Alimentiv #CrohnsDisease

Our purpose-built GI clinical trial solutions deliver consistency, confidence, and data you can trust, no matter where you are in your development journey. Let’s build a better trial: loom.ly/JpZ6qFA #GIIsOurWhy #Gastroenterology #ClinicalTrials #ImagingSolutions #PrecisionMedicine

✈️ We’re headed to the 7th annual Brazilian Week of Inflammatory Bowel Diseases (#SEBRADII2026)! Schedule a meeting with Saoirse Cameron, Business Development Manager, to see how Alimentiv’s GI expertise can support global studies from end to end. 👉 alimentiv.com/events/sebradi… 📅 August 19-22 📍 Booth #16 🌎 Campinas, São Paulo, Brazil #GIIsOurWhy

Your best trial starts with the right people. From global pharmaceutical companies to emerging biotechs, Alimentiv brings scientific rigor, operational excellence, and authentic collaboration to every program we touch. Find out how we can help advance your program, wherever you are in your pipeline 👉 loom.ly/xyE2kRE #ClinicalResearch #Gastroenterology #GIIsOurWhy

𝗪𝗵𝘆 𝗚𝗜? Because better data leads to better outcomes — and patients deserve nothing less. For more than 30 years, Alimentiv has led the science of GI clinical trials. From global trial design and patient recruitment to imaging, histopathology, and endpoints you can trust, our purpose‑built GI infrastructure delivers the rigor, consistency, and partnership sponsors need to accelerate development with confidence. We’re proud to have supported over 70% of IBD compounds in development — and we’re just getting started. ✨ 𝗚𝗜 𝗜𝘀 𝗢𝘂𝗿 𝗪𝗵𝘆. Watch our story. #GIIsOurWhy #Alimentiv #GIResearch #ClinicalTrials #DrugDevelopment #IBD

The VERDICT trial is coming to an end, and we’re grateful for the commitment from the patients, investigators, and clinical research teams who made this study possible. VERDICT is a randomized controlled treat-to-target trial in #UlcerativeColitis. This trial, sponsored and conducted by Alimentiv in collaboration with Takeda, will provide prospective data on optimal treatment targets that will help us understand which UC clinical target is associated with fewer complications and inform clinical guidelines, regulatory requirements, and future clinical trials. #TreatToTarget #ClinicalResearch #GIIsOurWhy

We understand the nuances of GI protocols. Dr. Nino Kiknadze from Aversi Clinic explains how working with Alimentiv CRAs, who are GI specialists and understand site workflows in detail, can support efficient trial execution. Read the full interview: loom.ly/PqQD77U #ClinicalResearch #Gastroenterology #GIIsOurWhy

𝗪𝗵𝗲𝗻 𝗶𝘁 𝗰𝗼𝗺𝗲𝘀 𝘁𝗼 𝗚𝗜 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵, 𝗲𝘅𝗽𝗲𝗿𝗶𝗲𝗻𝗰𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀. We’re a trusted scientific partner for sponsors advancing therapies for ulcerative colitis, Crohn’s disease, and related indications. This depth of GI-focused scientific leadership allows us to address scientific and operational challenges with precision, accelerate timelines, and generate data sponsors and regulators trust. Discover how our GI expertise can strengthen your program: loom.ly/ZHLio08 #GIIsOurWhy #IBDResearch #ClinicalTrials #Gastroenterology #CROLeadership

Need a CRO that understands the complexities of celiac disease? Alimentiv combines decades of GI expertise with a purpose-built, proven approach to trial design, imaging, and site selection that that recruit patients faster than average, plus a global network spanning 5,000+ sites across 60+ countries. We’ve helped shape IBD endpoints and advanced GI therapies - now we’re applying that knowledge to accelerate celiac research to bring new therapies to patients, faster. See how we can support your celiac trial. loom.ly/vYXau5c #CeliacDisease #ClinicalTrials #GIResearch #CRO #Alimentiv

𝗛𝗮𝗽𝗽𝘆 #𝗣𝗿𝗶𝗱𝗲 𝗠𝗼𝗻𝘁𝗵 𝗳𝗿𝗼𝗺 𝗔𝗹𝗶𝗺𝗲𝗻𝘁𝗶𝘃! 🌈 Pride reminds us that belonging is at the foundation of our organization. We're proud to bring our whole selves to work, supported by our LGBTQ+ Employee Resource Group that provides education, advocacy, and connection. Diversity in our workplace and in clinical research is key to the science we do. 🏳️‍🌈⚧️🏳️‍⚧️ Wishing everyone a joyful, safe, and proud month. #PrideMonth #Pride2026 #LGBTQ #InclusiveResearch #LoveIsLove